

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 399632001920

Application Number 02/04/02

RECEIVED

Applicant

Alessandro SETTE, et al.

AUG 02 2002

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

RECEIVED

JUL 17 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/1986	4,599,230	Milich et al.	424	189.1	
	2.	07/1991	5,028,425	Good et al.	424	191.1	
	3.	08/1994	5,342,774	Boon et al.	435	371	
	4.	04/1993	5,200,320	Sette et al.	435	7.24	
	5.	04/1995	5,405,940	Boon et al.	530	328	
	6.	10/1995	5,462,871	Boon-Falleur et al.	435	354	
	7.	04/1996	5,503,829	Ladant et al.	424	192.1	
	8.	09/1997	5,662,907	Kubo et al.	424	185.1	
	9.	04/1998	5,736,142	Sette et al.	424	185.1	
	10.	05/1998	5,750,395	Fikes et al.	435	325	
	11.	11/1998	5,840,303	Chisari et al.	424	152.1	
	12.	03/2000	6,037,135	Kubo et al.	435	7.24	
	13.	05/2000	6,063,900	Melief et al.	530	327	
	14.	06/2000	6,075,122	Cheever et al.	530	350	

COPY OF PAPERS
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	15.	01/1982	EP 44710	Europe			
	16.	06/1987	EP 0226513	Europe			
	17.	06/1989	EP 0346022	Europe			
	18.	08/1996	EP 0534615	Europe			
	19.	08/1996	EP 0728764	Europe			
	20.	02/1992	WO 92/02543	WIPO			
	21.	08/1992	WO 92/12996	WIPO			
	22.	11/1992	WO 92/21033	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632001920

Application Number 09/189,702

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

TECH CENTER 1600/2900

RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	23.	03/1993 WO 93/03753 WIPO
	24.	03/1993 WO 93/03764 WIPO
	25.	09/1993 WO 93/17095 WIPO
	26.	11/1993 WO 93/22338 WIPO
	27.	02/1994 WO 94/03205 WIPO
	28.	03/1994 WO94/05304 WIPO
	29.	05/1994 WO 94/11738 WIPO
	30.	04/1995 WO 95/11255 WIPO
	31.	08/1995 WO 95/23234 WIPO
	32.	02/1997 WO 97/04802 WIPO
	33.	08/1997 WO 97/29195 WIPO
	34.	Alexander et al. "Generation of Tumor-specific Cytolytic T Lymphocytes from Peripheral Blood of Cervical Cancer Patients by In Vitro Stimulation with a Synthetic Human Papillomavirus Type 16 E7 Epitope" Am. J. Obstet. Gynecol. 175:1586-1593 (1996)
	35.	Alexander et al., J. Immunol. (1997) 159:4753-4761
	36.	Altfeld et al., J. Virol. (2001) 75:1301-1311
	37.	Benjamin et al., Nature (1991) 351:74-77
	38.	Bergmann et al., J. Virol. (1994) 68:5306-5310
	39.	Bertoni et al., J. Clin. Invest. (1997) 100:503-513
	40.	Bjorkman et al. "Structure of the Human Class I Histocompatibility Antigen HLA-A2" Nature 329:506 (1987)
	41.	Boel et al., Immunity (1995) 2:167
	42.	Boon. Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy" Int. J. Cancer 54:177-180 (1993)
	43.	Bosisio et al., Gazz. Chim. Ital. (1967) 97(12):1848-1857
	44.	Bruss. "A Short Linear Sequence in the Pre-S Domain of the Large Hepatitis B Virus Envelope Protein Required from Virion Formation" J. Virology 71(12):9350-9357 (1997)
	45.	Buus et al. "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia" Science 242:1045-1047 (1988)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632001920

Application Number 09/189,702

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

46. Carreno et al. "HLA-B37 and HLA-A2.1 Molecules Bind Largely Nonoverlapping Sets of Peptides" Proc. Natl. Acad. Sci. USA 87:3420-3424 (1990)
47. Castellanos et al., Gynecologic Oncology (2001) 82:77-83
48. Castellanos et al., Oncology/Hematology (2001) 39:133-138
49. Celis et al. "Identification of Potential CTL Epitopes of Tumor Associated Antigen MAGE-1 for Five Common HLA-A Alleles" Molec. Immunol. 3:1423-1430 (1994)
50. Celis et al. "Epitope Selection and Development of Peptide Based Vaccines to Treat Cancer" Cancer Biology 6:329-336 (1995)
51. Chang et al., J. Immunol. (1999) 162:1156-1164
52. Chen and Parham, Nature (1989) 337:743-745
53. Cotran et al. (ed.) Robbins Pathologic Basis of Disease, 4th ed., W.B. Saunders Co., Philadelphia pp. 296-299 (1989)
54. Culmann et al., (1991) 146(5):1560-1565
55. De Bruijn et al. "Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses" Eur. J. Immunol. 21:2963-2970 (1991)
56. Del Val et al., Cell (1991) 66:1145-1153
57. DiBrino et al. "Endogenous Peptides Bound to HLA-A3 Possess a Specific Combination of Anchor Residues That Permit Identification of Potential Antigenic Peptides" Proc. Nat'l. Acad. Sci. USA 90:1508-1512 (1993)
58. Dibrino et al., J. Immunol. (1993) 151:5930-5935
59. Diepolder et al., J. Virol. (1997) 71(8):6011-6019
60. Ding et al. "Cloning and Analysis of MAGE-1-Related Genes" Biochem. Biophys. Res. Commun. 202(1):549-555 (1994)
61. Ding et al., Immunity (1998) 8:403-411
62. Doolan et al., Immunity (1997) 7:97-112
63. Doolan et al., J. Immunol. (2000) 165:1123-1137
64. Edgington. "How Sweet It Is: Selectin-Mediating Drugs" Biotechnology 10:383-389 (1992)
65. Eisenlohr et al., J. Exp. Med. (1992) 175:481-487
66. Engelhard et al. "Structure of Peptides Associated with MHC Class I Molecules" Curr. Opin. Immunol. 6:13-23 (1994)
67. Falk et al., J. Exp. Med. (1991) 174:425-434
68. Falk et al. "Allele-specific Motifs Revealed by Sequencing of Self-peptide Eluted from MHC Molecules" Nature 351:290-296 (1991)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 399632001920

Application Number 09/119,702

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

JUL 12 2002

(Use several sheets if necessary)

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

- | | |
|-----|--|
| 69. | Feltkamp et al. "Vaccination with Cytotoxic T Lymphocyte Epitope-containing Peptide Protects Against a Tumor Induced by Human Papillomavirus Type 16-transformed Cells" Eur. J. Immunol. 23:2242-2249 (1993) |
| 70. | Foon. "Biological Response Modifiers: the New Immunotherapy" Cancer Res. 49:1621-1639 (1989) |
| 71. | Fynan et al. "DNA Vaccines: Protective Immunizations by Parental, Mucosal, and Gene-gun Inoculations" Proc. Nat'l. Acad. Sci. USA 90:11478-11482 (1993) |
| 72. | Gambacorti-Passerini et al., Clin. Cancer Res. (1997) 3:675-683 |
| 73. | Gaugler et al. "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes" J. Exp. Med. 179(3):921-930 (1994) |
| 74. | Gavioli et al., Proc. Natl. Acad. Sci. USA (1992) 89:5862-5866 |
| 75. | Gonzalez et al., Parasite Immunology (2000) 22:501-514 |
| 76. | Guo et al., Nature (1992) 360:364-366 |
| 77. | Hayashi et al. "Molecular Cloning and Characterization of the Gene Encoding Mouse Melanoma Antigen by cDNA Library Transfection" J. Immunol. 149:1223-1229 (1992) |
| 78. | Henderson et al. "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation" Science 255:1264-1266 (1992) |
| 79. | Hill et al., Nature (1992) 360:434-439 |
| 80. | Huczko et al., J. Immunol. (1993) 151:2572-2587 |
| 81. | Hunt et al. "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry" Science 255:1261-1263 (1992) |
| 82. | Hurtenbach et al. "Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice by Treatment with a Class II Major Histocompatibility Complex-blocking Peptide" J. Exp. Med. 177:1494-1504 (1993) |
| 83. | Ishioka et al., J. Immunol. (1999) 162:3915-3925 |
| 84. | Jameson and Bevan, Eur. J. Immunol. (1992) 22:2663-2667 |
| 85. | Jardetzky et al. "Identification of Self Peptides Bound to Purified HLA-B27" Nature 353:326-329 (1991) |
| 86. | Jiang et al. "Role of CD8* T Cells in Murine Experimental Allergic Encephalomyelitis" Science 256:1213-1215 (1992) |
| 87. | Kannagi et al. "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells" J. of Virol. 66(5):2928-2933 (1992) |
| 88. | Karin et al J. Exp. Med. 180:2227-2237 (1994) |
| 89. | Kast et al., J. Immunol. (1994) 152:3904-3912 |

EXAMINER:

DATE CONSIDERED:

5/21/2003

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 399632001920

Application Number 09/189,702

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

TECH CENTER 1600/2900

JUL 17 2002

RECEIVED

- | | |
|------|---|
| 90. | Kast et al., Eur. J. Immunol. (1993) 23:1189-1192 |
| 91. | Kawakami et al., J. Immunol. (1995) 154:3961-3968 |
| 92. | Kawashima et al., "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors" Human Immunol. (1998) 59:1-14 |
| 93. | Knuth et al. "Cellular and Humoral Immune Responses Against Cancer: Implication for Cancer Vaccines" Curr. Opinion Immunol. 3:659-664 (1991) |
| 94. | Koh et al. "Less Mortality but More Relapses in Experimental Allergic Encephalomyelitis in CDB ⁻ Mice" Science 256:1210-1213 (1992) |
| 95. | Kozlowski et al., J. Exp. Med. (1992) 175:1417-1422 |
| 96. | Krieger et al. "Single Amino Acid Changes in DR and Antigen Define Residues Critical for Peptide-MHC Binding and T Cell Recognition" J. Immunol. 146:2331-2340 (1991) |
| 97. | Lamonica et al., Hepatology (1999) 30:1088-1098 |
| 98. | Lehniger. "Principles of Biochemistry" Worth Publishers, Inc. NY; pp. 100-101 (1982) |
| 99. | Lipford et al., J. Immunol. (1993) 150:1212-1222 |
| 100. | Lustgarten et al., "Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A2.1 and Human CD.8" Human Immunology (1997) 52:109-118 |
| 101. | Maier et al., (1994) 40:306-308 |
| 102. | Maryanski et al. "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers" Cell 60:63-72 (1990) |
| 103. | Melief et al. "T-Cell Immunotherapy of Cancer" Res. Immunol. 142:425-429 (1991) |
| 104. | Melief et al., Cancer Surveys (1992) 13:81-99 |
| 105. | Miller et al. "Suppressor T Cells Generated by Oral Tolerization to Myelin Basic Protein to Suppress Both In Vitro and In Vivo Immune Responses by the Release of Transforming Growth Factor β After Antigen-specific Triggering" Proc. Nat'l. Acad. Sci. USA 89:421-425 (1992) |
| 106. | Morrison et al. "Identification of the Nonamer Peptide from Influenza A Matrix Protein and the Role of Pockets of HLA-A2 in Its Recognition by Cytotoxic T Lymphocytes" Eur. J. Immunol. 22:903-907 (1992) |
| 107. | Niedermann et al., Immunol. Rev. (1999) 172:29-48 |
| 108. | Niedermann et al., Proc. Natl. Acad. Sci. USA (1996) 93:8572-8577 |
| 109. | Oaks et al. "Molecular Cytogenetic Mapping of the Human Melanoma Antigen (MAGE) Gene Family to Chromosome Region Xq27-qtr: Implications for MAGE Immunotherapy" Cancer Res. 54:1627-1629 (1994) |
| 110. | Ochoa-Garay et al. Molecular Immunology 34:273-281 (1997) |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

AUG 02 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900

Form PTO-1449

Docket Number 399632001920

Application Number 09/189,702

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

JUL 17 2002

RECEIVED

- | | |
|------|--|
| 111. | Pamer et al. "Precise Prediction of a Dominant Class I MHC-restricted Epitope of <i>Listeria monocytogenes</i> " <i>Nature</i> 353:852-855 (1991) |
| 112. | Parker et al. "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> " <i>J. Biol. Chem.</i> 267(8):5451-5459 (1992) |
| 113. | Parker et al. "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2" <i>J. Immunol.</i> 149:3580-3587 (1992) |
| 114. | Parker et al. "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains" <i>Journal of Immunology</i> 152(1):163-175 (1994) |
| 115. | Paul (ed.), <i>Fundamental Immunology</i> , 2 nd ed., Raven Press, NY, pp. 473-487 (1989) |
| 116. | Paul (ed.), <i>Fundamental Immunology</i> , 3 rd ed., Raven Press, NY, pp. 976-978 (1993) |
| 117. | Preisler-Adams et al. "Complete Nucleotide Sequence of a Hepatitis B Virus, Subtype adw2, and Identification of Three Types of C Open Reading Frames" <i>Nucleic Acids Res.</i> 21:2258 (1993) |
| 118. | Prezzi et al., <i>Eur. J. Immunol.</i> (2001) 31:894-906 |
| 119. | Rammensee et al. "Peptides Naturally Presented by MHC Class I Molecules" <i>Annu. Rev. Immunol.</i> 11:213-244 (1993) |
| 120. | Rammensee et al. "MHC Ligands and Peptide Motifs: First Listing" <i>Immunogenetics</i> 41(4):178-228 (1995) |
| 121. | Rammensee et al. "SYFPEITHI: Database for MHC Ligands and Peptide Motifs" <i>Immunogenetics</i> 50(3-4):213-219 (1999) |
| 122. | Rehermann et al., <i>J. Clin. Invest.</i> (1996) 97:1655-1665 |
| 123. | Ressing et al. "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides" <i>J. Immunol.</i> 154:5934 (1995) |
| 124. | Rickinson. "Immune Intervention Against Virus-associated Human Cancers" <i>Annals of Oncology</i> 6(Supp. 1): 69-71 (1995) |
| 125. | Rivoltini et al., <i>J. Immunol.</i> (1995) 154:2257-2265 |
| 126. | Romero et al. "H-2Kd-restricted Antigenic Peptides Share a Simple Binding Motif" <i>J. Exp. Med.</i> 174:603-612 (1991) |
| 127. | Rothbard, <i>Current Opinion in Immunology</i> (1989) 2:99-105 |
| 128. | Rotzschke et al. "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y" 249:283-287 (1990) |
| 129. | Rotzschke et al. "Isolation and Analysis of Naturally Processed Viral Peptides As Recognized by Cytotoxic T Cells" <i>Nature</i> 348:252-254 (1990) |
| 130. | Rotzschke et al. "Naturally Occurring Peptide Antigens Derived from the MHC Class-I-restricted Processing Pathway" <i>Immunology Today</i> 12(12):447-455(1991) |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered. If not, draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

AUG 3 2 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449

Docket Number 399632001920

Application Number 09/189,702

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Alessandro SETTE, et al.

Filing Date November 10, 1998

Group Art Unit 1644

Mailing Date July 5, 2002

(Use several sheets if necessary)

- | | |
|------|--|
| 131. | Rotzschke et al. "Peptide Motifs of Closely Related HLA Class I Molecules Encompass Substantial Differences" Eur J. Immunol. 22:2453-2456 (1992) |
| 132. | Rudinger. "Characteristics of the Amino Acids As Components of a Peptide Hormone Sequence" in <u>Peptide Hormones</u> , Parsons (ed.), University Park Press, pp. 1-7 (1976) |
| 133. | Ruppert et al. "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules" Cell 74(5):929-937 (1993) |
| 134. | Sarobe et al. "Induction of Antibodies Against a Peptide Hapten Does Not Require Covalent Linkage Between the Hapten and a Class II Presentable T Helper Peptide" Eur. J. Immunol. 21:1555-1558 (1991) |
| 135. | Schaeffer et al. Proc. Natl. Acad. Sci. USA 86:4649 (1989) |
| 136. | Scognamiglio et al., J. Immunol. (1999) 162:6681-6689 |
| 137. | Sette et al. "Prediction of Major Histocompatibility Complex Binding Regions by Sequence Pattern Analysis" Proc. Nat'l. Acad. Sci. USA 86:3296-3300 (1989) |
| 138. | Sette et al. "Random Association between the Peptide Repertoire of A2.1 Class I and Several Different DR Class II Molecules" J. Immunol. 147:3893-3900 (1991) |
| 139. | Sette et al., J. Immunol. (1994) 153:5586-5592 |
| 140. | Sette and Sidney, Curr. Opin. Immunol. (1998) 10:478-482 |
| 141. | Sette et al., in Persistent Viral Infections, Ahmed and Chen (Eds.), John Wiley & Sons (1999) |
| 142. | Sette et al., Immunodominance and Breadth of Cellular Responses (2001) In Press |
| 143. | Shanker et al. "Three Regions of HIV-1 gp160 Contain Clusters of Immunodominant CTL Epitopes" (Abstract) Immunology Letters 52(1):23-30 (1996) |
| 144. | Shastri et al., J. Immunol. (1995) 155:4339-4346 |
| 145. | Sherman et al., J. Exp. Med. (1992) 175:1221-1226 |
| 146. | Shimojo et al. "Specificity of Peptide Binding by the HLA-A2.1 Molecule" J. of Immunol. 143(9):2939-2947 (1989) |
| 147. | Slingluff et al. "Recognition of Human Melanoma Cells by HLA-A2.1-restricted Cytotoxic T Lymphocytes Is Mediated by At Least Six Shared Peptide Epitopes" J. Immunol. 150:2955-2960 (1993) |
| 148. | Snoke et al., J. Immunol. (1993) 151:6815-6821 |
| 149. | Storkus et al. "Identification of Human Melanoma Peptides Recognized by Class I Restricted Tumor Infiltrating T Lymphocytes" J. Immunol. 151:3719-3727 (1993) |
| 150. | Tangri et al., Journal of Experimental Medicine (2001) In Press |
| 151. | Threlkeld et al., J. Immunol. (1997) 159:1648-1657 |
| 152. | Traversari et al. "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

AUG 02 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449		Docket Number 399632001920	Application Number 09/189,702
INFORMATION DISCLOSURE CITATION ON AN APPLICATION (Use several sheets if necessary)		Applicant Alessandro SETTE, et al.	
		Filing Date November 10, 1998	Group Art Unit 1644
		Mailing Date July 5, 2002	
		Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E" J. Exp. Med. 176:1453-1457 (1992)	
	153.	Tsai et al., J. Immunol. (1997) 1796-1802	
	154.	Urban et al. "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy" Cell 59:257-271 (1989)	
	155.	Van der Bruggen et al. "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma" Science 254:1643-1647 (1991)	
	156.	Van Der Most et al., J. Immunol. (1996) 157:5543-5554	
	157.	Van Der Most et al., Virology (1997) 71:5110-5114	
	158.	Van Der Most et al., Virology (1998) 240:158-167	
	159.	Viret et al. "Recognition of Shared Melanoma Antigen by HLA-A2 Restricted Cytolytic T Cell Clones Derived from Human Tumor-infiltrating Lymphocytes" Eur. J. Immunol. (1993)	
	160.	Vitiello et al. "Development of a Lipopeptide Based Therapeutic Vaccine to Treat Chronic HBV Infection" J. Clin. Invest. 95:341-349 (1995)	
	161.	Vitiello et al., J. Immunol. (1996) 157:5555-5562	
	162.	Wei et al. "HLA-A2 Molecules in an Antigen-Processing Mutant Cell Contain Signal Sequencederived Peptides" Nature 356:443-446 (1992)	
	163.	Wentworth et al., Eur. J. Immunol. (1996) 26:97-101	
	164.	Weynants et al. "Expression of MAGE Genes by Non-Small-Cell Lung Carcinomas" Int. J. Cancer 56:826-829 (1994)	
	165.	Wilson et al., J. Virol. (2001) 75:4195-4207	
	166.	Wizel et al., J. Clin. Invest. (1998) 102:1062-1071	
	167.	Wraith et al. "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy" Cell 59:247-255 (1989)	
	168.	Wysocka et al. "Class I H-2d-Restricted Cytotoxic T Lymphocytes Recognize the Neuraminidase Glycoprotein of Influenza Virus Subtype N1" Journal of Virology 64(3):1028-1032 (1990)	
	169.	Yewdell and Bennick, Annu. Rev. Immunol. (1999) 17:51-88	
	170.	Yoon et al., Virus Research (1998) 54:23-29	
	171.	York and Rock, Annu. Rev. Immunol. (1996) 14:369-396	
	172.	Zakut et al, "Differential Expression of MAGE-1, -2, and -3 Messenger RNA in Transformed and Normal Human Cell Lines" Cancer Res. 53:5-8 (1993)	
	173.	Zhang et al., Proc. Natl. Acad. Sci. USA (1993) 90(6):2217-2221	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.		5/31/2003	

PTO/SB/08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

AUG 02 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900